`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________
`
`MYLAN PHARMACEUTICALS INC.
`
`Petitioner
`
`v.
`
`JANSSEN ONCOLOGY, INC.
`
`Patent Owner
`____________________________
`
`Case No. IPR2016-01332
`U.S. Patent No. 8,822,438
`____________________________
`
`DECLARATION OF ROBERT D. SWANSON
`IN SUPPORT OF MOTION FOR PRO HAC VICE ADMISSION OF
`ROBERT D. SWANSON
`
`
`MYLAN PHARMS. INC. EXHIBIT 1087 PAGE 1
`
`
`
`I, Robert D. Swanson, declare as follows:
`
`1.
`
`2.
`
`I am an associate in the patent litigation group at Perkins Coie LLP.
`
`I am a member in good standing of the Bar of the State of California.
`
`I am also admitted to practice before the United States Courts of Appeals for the
`
`Federal Circuit.
`
`3. My Bar membership numbers are CA 295159.
`
`4.
`
`I have been practicing law for over a year, not including clerkships
`
`with Judge Whyte and Judge Koh on the United States District Court for the
`
`Northern District of California and Chief Judge Prost of the United States Court of
`
`Appeals for the Federal Circuit. During my time in practice, I have focused on
`
`litigating patent cases, specifically pharmaceutical patent cases.
`
`5. More generally, I have represented the Petitioner and/or its various
`
`related entities in litigating significant pharmaceutical patent cases, such as the
`
`following infringement cases:
`
`
`
`Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc., Civil
`
`Action No. 1:14-cv-01278 (U.S. District Court for the District of
`
`Delaware);
`
`
`
`Teva Pharmaceuticals USA Inc. v. Sandoz Inc., Civil Action No.
`
`17-1575 (U.S. Court of Appeals for the Federal Circuit);
`
`MYLAN PHARMS. INC. EXHIBIT 1087 PAGE 2
`
`
`
`
`
`Yeda Research and Development Co. v. Mylan Pharmaceuticals Inc.,
`
`Civil Action Nos. 17-1594, 17-1595, 17-1596 (U.S. Court of Appeals
`
`for the Federal Circuit);
`
`
`
`
`
`AstraZeneca AB v. Mylan Pharmaceuticals Inc., No. 3:13-cv-04022
`
`(U.S. District Court for the District of New Jersey);
`
`Horizon Pharma, Inc. v. Mylan Pharmaceuticals Inc., Civil Action
`
`No. 15-cv-03327 (U.S. District Court for the District of New Jersey);
`
`and
`
`
`
`Horizon Pharma, Inc. v. Mylan Pharmaceuticals Inc., Civil Action
`
`No. 16-cv-04921 (U.S. District Court for the District of New Jersey).
`
`6.
`
`I have never been disbarred, sanctioned or cited for contempt by any
`
`court or administrative body. I am not currently suspended in any bar or by any
`
`court or administrative body.
`
`7.
`
`I have never had a court deny my application for admission to
`
`practice.
`
`8.
`
`I am familiar with the subject matter of this proceeding. In addition to
`
`U.S. Patent No. 8,822,438 (“the ’438 patent”) and its prosecution history, I am
`
`familiar with the technology at issue and Zytiga, the pharmaceutical product for
`
`which the ’438 patent is listed by Janssen in FDA’s publication, Approved Drug
`
`Products with Therapeutic Equivalence Evaluations, commonly referred to as the
`
`MYLAN PHARMS. INC. EXHIBIT 1087 PAGE 3
`
`
`
`“Orange Book.” I have been litigating issues surrounding Zytiga for more than a
`
`year in BTG Int’l Ltd. v. Actavis Labs. FL, Inc., Civil Action No. 2:15-cv-05909
`
`(D.N.J.), on behalf of Mylan Pharmaceuticals and Mylan Inc.
`
`9.
`
`In connection with my work on the Zytiga litigation, I have become
`
`familiar with the prior art references that are the subject of this proceeding.
`
`10. Given my familiarity with the underlying facts and my litigation
`
`experience with the Federal Rules of Evidence, I have experience and expertise
`
`important to representing Mylan’s interests in this matter.
`
`11.
`
`I have read and will comply with Office Patent Trial Practice guide
`
`and the Board's Rules of Practice for Trials, as set forth in Part 42 of 37 C.F.R.
`
`12.
`
`I agree to be subject to the United States Patent and Trademark Office
`
`Code of Professional Responsibility set forth in 37 C.F.R.§§ 11.101 et. seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`13.
`
`I have not previously applied for admission pro hac vice before the
`
`United States Patent and Trademark Office.
`
`14.
`
`I hereby declare that all statements made herein of my own
`
`knowledge are true and that all statements made on information and belief are
`
`believed to be true; and further that these statements are made with the knowledge
`
`that willful false statements and the like are punishable by fine, imprisonment, or
`
`both, under Section 1001 of Title 18 of the United States Code.
`
`MYLAN PHARMS. INC. EXHIBIT 1087 PAGE 4
`
`
`
`
`
`Dated: April 4, 2017
`
`
`
`
`/s/ Robert D. Swanson
`Robert D. Swanson
`
`MYLAN PHARMS. INC. EXHIBIT 1087 PAGE 5
`
`